Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics in Surgery ›› 2016, Vol. 16 ›› Issue (04): 391-396.DOI: 10.3969/j.issn.1009-976X.2016.04.005

Previous Articles     Next Articles

Expressions and its role of miR-20b in breast cancer

TANG Wei, YE Xigang, PAN Lingxiao, GAO Jin, CHEN Lun, Zhang Xiaoshen, ZHENG Wenbo   

  • Contact: ZHENG Wenbo

miR-20b在乳腺癌的表达及对乳腺癌细胞增殖的影响

唐炜 叶熹罡 潘凌霄 高进 陈伦 张晓申 郑文博   

  1. 广州医科大学附属第一医院
  • 通讯作者: 郑文博

Abstract: 【Abstract】〓Objective〓To investigate the expressions of miR-20b in breast cancer and its role in breast cancer cells in vitro. Methods〓Total RNA from 134 breast cancer tissues were isolated for miR-20b quantitative analysis by real-time RT-PCR. The associations between miR-20b expression levels and clinicopathological features were analyzed. Breast cancer cells were transfected with miR-20b inhibitors,then CCK-8 and flow cytometry methods were used to detect the proliferation and apoptosis of the cells. Results〓The expression of miR-20b was up-regulated in breast cancer tissues compared with those in adjacent tissues (P<0.001). There was a significant correlation between miR-20b expression and tumor stage,distal metastasis and Ki67 expression (P<0.05). High miR-20b expression was positively correlated with shorter DFS and OS (P<0.05). The down-expression of miR-20b resulted in decrease in the rate of cell proliferation and increase in cell apoptosis. Conclusion〓Higher miR-20b is associated with poor prognosis of breast cancer and may serve as independent prognostic markers for breast cancer cells.

Key words: Breast cancer, miR-20b , RT-PCR

摘要: 【摘要】〓目的〓观察miRNA-20b(miR-20b)在乳腺癌组织中的表达情况和对乳腺癌细胞株生长凋亡的影响。方法〓运用实时定量RT-PCR检测134例乳腺浸润性导管癌组织miR-20b的表达,并与临床病理资料和生存时间进行相关分析;瞬时转染miR-20b抑制物到乳腺癌细胞中,CCK-8法和流式细胞术检测细胞增殖和凋亡情况。结果〓miR-20b在乳腺癌组织中表达量明显高于癌旁组织(P<0.001)。其表达与肿瘤大小、远处转移情况及Ki67表达相关(P<0.001)。miR-20b高表达组病人的无病生存期(DFS)和总生存期(OS)短于低表达组(P<0.05)。转染miR-20b抑制物后,细胞增殖减弱(P<0.05),凋亡增强(P<0.05)。结论〓乳腺癌组织中miR-20b表达与乳腺癌预后相关,可作为乳腺癌恶性程度的预测指标。

关键词: 实时定量RT-PCR, miR-20b, 乳腺癌

CLC Number: